AI-powered algorithms to drive the Uveitis Treatment Market at a CAGR around 6%

Uveitis is a condition that causes inflammation in the uvea, the middle layer of the eye. It can cause vision loss and can be associated with several underlying diseases. Uveitis treatment includes a range of medications and surgical interventions aimed at reducing inflammation and managing underlying conditions.

Telehealth is being broadly employed, especially in the post-pandemic era. Telehealth trendline does follow a wider move has majority of healthcare communications are being done online. The new offerings like digital appointment reminders (text, email, etc.), two-way texting, AI-powered virtual assistants are being doled out by the key participants in healthcare vertical through collaborations with players dealing in these updations. Reviews and ratings are also being used as benchmarks by patients. This would be the situation with Uveitis Treatment Market in the forecast period.

Uveitis Treatment Market Revenues Poised to Reach US$ 847.8 Mn by 2024-End.

It's a known fact that healthcare journeys are not linear every time. As such, digital advertising is creeping the healthcare vertical. This would be followed by the usage of marketing personalization, that too, while keeping patient's privacy intact. Healthcare IT would thus cause turbulence in the Uveitis Treatment Market in the forecast period. In other words, substantiation through digital transformation would be cornerstone of Uveitis Treatment Market in the next 10 years.

Get Free Sample Copy of Uveitis Market @ https://www.persistencemarketresearch.com/samples/3596

The US$ 497 Mn uveitis treatment market is likely to expand at a stable CAGR of 6.5% over the next eight years. In 2017, the market is expected to witness nearly 6.7% Y-o-Y growth over 2016. During 2016-2024, Persistence Market Research predicts a positive growth outlook for the global uveitis treatment market, influenced by several growth drivers, restraints, trends, and opportunities.

Company Profiles

Allergan, Inc.,
Bausch & Lomb Incorporated.
Novartis AG (Alcon Laboratories Inc.)
AbbVie Inc.
Santen Pharmaceutical Co., Ltd
Eyegate Pharmaceuticals, Inc.
Alimera Sciences, Inc.
pSivida Corp.

While surge in autoimmune disorders is identified to primarily generate the demand for uveitis, the market has been witnessing strong emergence of immunosuppressive therapies to treat uveitis since the past few years, which is expected to create a new set of opportunities for leading players in near future.

"Some of the leading companies in the uveitis treatment marketplace have been investing in new, improved product launches since the past decade. While a significant number of uveitis drugs are already in the pipeline, increasing in-licensing approvals for new market entrants will boost the scope of treatment against uveitis, ultimately creating new lucrative opportunities," states Persistence Market Research.

Increasing demand for generic drugs also prompt at an important trend in the global uveitis treatment market that will reportedly generate a range of opportunities for established as well as new pharma players.

In addition to growing R&D activities in the field of eye disorders, rising optometric clinical practice will also provide an impetus to market growth.
With surging uveitis prevalence, a host of biological drug development projects is anticipated to push the potential of the uveitis treatment market.
Moreover, growing prevalence of TB associated with intermediate uveitis will continue to push the opportunities in intermediate uveitis segment.
Another proliferating trend in uveitis treatment market includes increasing demand for local steroid implants, especially for non-infectious posterior uveitis.

As corticosteroid mono-therapy is no more considered the first line treatment for uveitis, the market has been witnessing introduction of various modified corticosteroid medication and drug delivery methods since the recent past.
Major players in the segment are working to add novel drugs to their product portfolio.
R&D in topical agents segment will also benefit the market growth in near future.


Request For Customization@https://www.persistencemarketresearch.com/request-customization/3596

Segmentation by treatment type:

Corticosteroids
Immunosuppressants
Monoclonal antibodies
Cycloplegic agents
Antibodies
Antivirals
Antifungals
Analgesics

Corticosteroids will remain the largest segment, followed by antibiotics and monoclonal antibodies. While corticosteroids segment is foreseen to account for a dominant market share of over 21% in 2024, antibiotics segment is expected to witness the fastest growth at a CAGR of 8% - reaching beyond US$ 146 Mn over 2016-2024. Monoclonal antibodies segment will also exhibit healthy growth at a CAGR of 7%, reaching revenues worth US$ 142.7 Mn by the end of 2024.

Segmentation by disease type:

Anterior uveitis
Posterior uveitis
Intermediate uveitis
Panuveitis

Anterior uveitis segment will continue to dominate. Through 2024, this segment will capture around 60% value share, representing a value of over US$ 500 Mn. Posterior uveitis is also estimated for a considerable market value share of over 23% in 2024. Attributed to increased prevalence of TB in intermediate uveitis, the intermediate uveitis will possibly be the second fastest growing segment over the forecast period.

Segmentation by cause:

Infectious
Non-infectious
On the basis of cause, infectious uveitis will remain the larger segment with over 87% share by 2024 end but non-infectious uveitis is predicted to witness a higher CAGR of 7.4% during the eight-year period.

Segmentation by distribution channel:

Hospital pharmacies
Retail pharmacies
Online pharmacies
Drug stores

By distribution channel, hospital pharmacies segment will account for over 46% revenue share in 2024, whereas retail pharmacies segment is likely to capture around 30% share. Online pharmacies and drug stores segments will also witness healthy growth at over 6% CAGR during the aforementioned period.

Segmentation by region:

The report provides regional analysis that examines the global market classifying it into five key regions.

North America
Latin America
Europe
Asia Pacific (APAC)
Middle East and Africa (MEA)

North America, the largest and fastest growing regional market for uveitis treatment globally, will retain its dominant position over the assessed period. With over 34% market value share in 2024, this regional will possibly account for around US$ 290 Mn. Europe will remain the second key market with nearly 27% share by the end of forecast period, followed by Asia Pacific.

Click The "Purchase Now" Button Of Our Uveitis Market Report @ https://www.persistencemarketresearch.com/checkout/3596

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.